Remember
 
+
 
+
 Do You Know the Most Important and Timely Stock Plays During the Trading Week? View Our Power Rankings.
 
russurban Placed a 'Buy' Sentiment on SFET22 hours ago
russurban Followed SFET5 days ago
russurban Placed a 'Buy' Sentiment on VXRTMore than a week ago
stockpicks Placed a 'Buy' Sentiment on BYND3 days ago
stockpicks Followed BYND3 days ago
stockpicks Placed a 'Buy' Sentiment on HYREMore than a week ago
anonusers Placed a 'Buy' Sentiment on SFET4 days ago
anonusers Placed a 'Buy' Sentiment on INPX5 days ago
anonusers Placed a 'Buy' Sentiment on AMRNMore than a week ago
 
Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  SFET  •  RAD  •  WRTC  •  NFLX  •  OSTK  •  CGC  •  ARCI  •  LULU  •  SNAP  •  IRBT  Reserve Investor Relations Services for OTC Stocks at goalx.org

Fighting Cancer Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Fighting Cancer Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: cancer, oncology, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Fighting Cancer.

Generated with SpeculatingStocks Stock Theme Analytics Algorithm™ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to fighting cancer; however, a few may just somewhat depend and/or be indirectly related to fighting cancer. As always complete your own due diligence.


Fighting Cancer Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































386.488M
















108.54M




















198.107B
























244.572B






























































132.409B




























































54.418B






















































124.047B











Recent Fighting Cancer Headlines





Recent Fighting Cancer Posts (Pulses)




01/-0/2019: $LOXO Loxo Oncology leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology up 65% leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B in cash ($235 per share) at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $SNDX Syndax Pharmaceuticals provided 2019 clinical and corporate outlook -- data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19. -- Go to this Pulse Post



01/-0/2019: $REGN Regeneron Pharma & Sanofi (SNY) restructure global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. -- Go to this Pulse Post



01/-0/2019: $XBI Oncology stocks mostly lower after Bristol Myers (BMY) opts for attractively-valued cancer drug giant Celgene (CELG) in a $74B blockbuster deal. -- Go to this Pulse Post



01/-0/2019: $VCYT Veracyte entered strategic collaboration with Johnson & Johnson (JNJ) to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. -- Go to this Pulse Post



01/-0/2019: $ATNX Athenex entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharma to exclusively develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in humans in China. -- Go to this Pulse Post



01/-0/2019: $MRK Merck Keytruda received five new approvals in japan, including in advanced non-small cell lung cancer as adjuvant therapy for melanoma, and in advanced microsatellite instability-high tumors. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $LOXO Loxo Oncology up 65% leading oncology stocks higher after being acquired by Eli Lilly (LLY) for $8B in cash ($235 per share) at a 68% premium. -- Go to this Pulse Post



01/-0/2019: $SNDX Syndax Pharmaceuticals provided 2019 clinical and corporate outlook -- data from ENCORE I/O combination program in melanoma and ovarian cancer expected in 1Q19. -- Go to this Pulse Post



01/-0/2019: $REGN Regeneron Pharma & Sanofi (SNY) restructure global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. -- Go to this Pulse Post



01/-0/2019: $XBI Oncology stocks mostly lower after Bristol Myers (BMY) opts for attractively-valued cancer drug giant Celgene (CELG) in a $74B blockbuster deal. -- Go to this Pulse Post



01/-0/2019: $VCYT Veracyte entered strategic collaboration with Johnson & Johnson (JNJ) to advance the development and commercialization of novel diagnostic tests to detect lung cancer at its earliest stages, when the disease is most treatable. -- Go to this Pulse Post



01/-0/2019: $ATNX Athenex entered into a licensing and partnership agreement with Chongqing Jingdong Junzhuo Pharma to exclusively develop and commercialize KX2-391 for the treatment of actinic keratosis and oncology indications in humans in China. -- Go to this Pulse Post



01/-0/2019: $MRK Merck Keytruda received five new approvals in japan, including in advanced non-small cell lung cancer as adjuvant therapy for melanoma, and in advanced microsatellite instability-high tumors. -- Go to this Pulse Post